Advertisement

Archives of Women's Mental Health

, Volume 20, Issue 2, pp 243–247 | Cite as

Flibanserin and its discontents

  • Awais Aftab
  • Cheryl Chen
  • Jacob McBride
Review Article

Abstract

In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin’s safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido. Based on the review of literature, authors judge flibanserin to be modestly effective and reasonably safe, and discuss the differences in philosophical perspectives with less definitive answers.

Keywords

Flibanserin Hypoactive sexual desire disorder Female sexuality Women’s mental health Ethics 

Notes

Acknowledgements

The authors would like to thank Erum Ahmad and John DeMott for their helpful thoughts and suggestions.

Authors’ contributions

AA conceived of the subject and conceptualized the outline of the paper. The literature search, writing, and editing were done by all three authors collaboratively.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Funding

None

IRB approval

Not applicable

References

  1. Advisory Committee Meeting Document (2015) Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Bone, Reproductive and Urologic Drugs Advisory Committee Meeting, Drug Safety and Risk Management Advisory Committee. p. i-xvi. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm449090.pdf. Accessed 6 Mar 2016
  2. Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T (2005) Outcome measurement in female sexual dysfunction clinical trials: review and recommendations. J Sex Marital Ther 31:153–166CrossRefPubMedGoogle Scholar
  3. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Textual Revision. American Psychiatric Association, Washington DCCrossRefGoogle Scholar
  4. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, ArlingtonCrossRefGoogle Scholar
  5. BBC (2015, Aug 19) ‘Female Viagra’—a closer look at flibanserin. http://www.bbc.com/news/health-33984472. Accessed 6 Mar 2016
  6. Bolton D (2008) What is mental disorder?: an essay in philosophy, science, and values. Oxford University Press, OxfordCrossRefGoogle Scholar
  7. Brotto LA (2010) The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch Sex Behav 39:221–239. doi: 10.1007/s10508-009-9543-1 CrossRefPubMedGoogle Scholar
  8. Clayton AH, Dennerstein L, Fisher WA, Kingsberg SA, Perelman MA, Pyke RE (2010) Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J Sex Med 7:541–560. doi: 10.1111/j.1743-6109.2009.01628.x CrossRefPubMedGoogle Scholar
  9. Clayton AH, DeRogatis LR, Rosen RC, Pyke R (2012) Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM‐V revisions: 1. For women with incomplete loss of desire or sexual receptivity. J Sex Med 9:2027–2039. doi: 10.1111/j.1743-6109.2012.02850.x CrossRefPubMedGoogle Scholar
  10. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R, VIOLET Trial Investigators (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 9:1074–1085. doi: 10.1111/j.1743-6109.2011.02626.x CrossRefPubMedGoogle Scholar
  11. FDA (2015) ADDYI (flibanserin). FDA product labelling. p 3. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed 26 Mar 2016
  12. FDA (2016) CIALIS (tadalafil). FDA product labelling. p 17. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021368s027lbl.pdf. Accessed 4 Nov 2016
  13. Gellad WF, Flynn KE, Alexander GC (2015) Evaluation of flibanserin: science and advocacy at the FDA. JAMA 314:869–870. doi: 10.1001/jama.2015.8405 CrossRefPubMedGoogle Scholar
  14. Goldschmidt D (2015, August 18) ‘Female Viagra’ gets FDA approval. CNN. http://www.cnn.com/2015/08/18/health/female-viagra-fda-approval/. Accessed 6 Mar 2016
  15. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET (2016) Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 176:453–462. doi: 10.1001/jamainternmed.2015.8565 CrossRefPubMedGoogle Scholar
  16. Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, Lehrfeld K, Lee L, Kim MJ, Slagle AF, Beitz J (2016) FDA approval of flibanserin—treating hypoactive sexual desire disorder. N Engl J Med 374:101–104. doi: 10.1056/NEJMp1513686 CrossRefPubMedGoogle Scholar
  17. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M, BEGONIA Trial Investigators (2013) Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 10:1807–1815. doi: 10.1111/jsm.12189 CrossRefPubMedGoogle Scholar
  18. Kingsberg SA (2014) Attitudinal survey of women living with low sexual desire. J Womens Health (Larchmt) 23:817–823. doi: 10.1089/jwh.2014.4743 CrossRefGoogle Scholar
  19. Kingsberg SA, Althof SE (2011) Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. J Sex Med 8:3262–3270. doi: 10.1111/j.1743-6109.2011.02447.x CrossRefPubMedGoogle Scholar
  20. Meixel A, Yanchar E, Fugh-Berman A (2015) Hypoactive sexual desire disorder: inventing a disease to sell low libido. J Med Ethics 41:859–862. doi: 10.1136/medethics-2014-102596 CrossRefPubMedGoogle Scholar
  21. Nagoski E (2015) Nothing is wrong with your sex drive. The New York Times. http://www.nytimes.com/2015/02/27/opinion/nothing-is-wrong-with-your-sex-drive.html. Accessed 2 Feb 2016
  22. Stahl SM (2015) Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr 20:1–6CrossRefPubMedGoogle Scholar
  23. Sungur MZ, Gündüz A (2014) A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med 11:364–373. doi: 10.1111/jsm.12379 CrossRefPubMedGoogle Scholar
  24. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R, DAISY Trial Investigators (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 9:793–804. doi: 10.1111/j.1743-6109.2011.02595.x CrossRefPubMedGoogle Scholar
  25. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) (2000). Draft guidance for industry: female sexual dysfunction: clinical development of drug products for treatment. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1_02_C-FDA-Appendix-1.pdf. Accessed 6 Mar 2016
  26. Yuko E (2015) The FDA, finances and feminism: why the third time was the charm for so-called ‘female Viagra’. The Huffington Post. 2015, August 24. http://www.huffingtonpost.com/elizabeth-yuko/the-fda-finances-feminism_b_8021828.html. Accessed 6 Mar 2016

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  1. 1.Department of PsychiatryCase Western Reserve University/University Hospitals Cleveland Medical CenterClevelandUSA
  2. 2.Center of Excellence in Public Service PsychiatryUniversity of Pittsburgh Western Psychiatric Institute and ClinicPittsburghUSA

Personalised recommendations